Literature DB >> 1725245

HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation.

H G Skelton1, K J Smith, T L Barrett, G P Lupton, J H Graham.   

Abstract

The antibody HMB-45 used as an immunohistochemical reagent has often been labeled as a marker for melanoma, even though some benign lesions have been noted to show positive staining reactions with this reagent. Biopsy specimens from 225 benign and malignant melanocytic lesions were examined after immunoperoxidase staining for S-100 protein and HMB-45. The lesions studied included common acquired nevi, spindle cell and epithelioid cell nevi (Spitz nevi), cellular blue nevi, deep penetrating nevi, congenital nevi, nevi from hormonally reactive areas (genital), malignant melanoma, and desmoplastic malignant melanoma. A positive reaction for HMB-45 was seen in the dermal component in a high percentage of each of these types of lesions except for the common acquired nevi and the desmoplastic malignant melanomas that were uniformly negative for HMB-45 in the dermal component. HMB-45 correlates with melanosome production and thus a melanocytic origin of HMB-45-positive cells. HMB-45 may correlate best with factors that stimulate melanocytic proliferation and production of melanosomes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725245     DOI: 10.1097/00000372-199113060-00004

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  13 in total

1.  The correlation of TRPM1 (Melastatin) mRNA expression with microphthalmia-associated transcription factor (MITF) and other melanogenesis-related proteins in normal and pathological skin, hair follicles and melanocytic nevi.

Authors:  Song Lu; Andrzej Slominski; Sung-Eun Yang; Christine Sheehan; Jeffrey Ross; J Andrew Carlson
Journal:  J Cutan Pathol       Date:  2010-04       Impact factor: 1.587

2.  The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).

Authors:  K S Clarkson; I C Sturdgess; A J Molyneux
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

Review 3.  Primary malignant melanoma of esophagus: a case report and review of literature.

Authors:  Yue-Ming Hu; Ji-Dong Yan; Yang Gao; Qing-An Xia; Yu Wu; Zhi-Yong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 4.  My approach to atypical melanocytic lesions.

Authors:  K S Culpepper; S R Granter; P H McKee
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

Review 5.  Investigation of cAMP microdomains as a path to novel cancer diagnostics.

Authors:  Garrett Desman; Caren Waintraub; Jonathan H Zippin
Journal:  Biochim Biophys Acta       Date:  2014-09-07

6.  Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

Authors:  P Rudolph; T Lappe; C Schubert; D Schmidt; R M Parwaresch; E Christophers
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

7.  Capsular nevus versus metastatic malignant melanoma - a diagnostic dilemma.

Authors:  Justin Davis; Jeevitha Patil; Nail Aydin; Aparajita Mishra; Subhasis Misra
Journal:  Int J Surg Case Rep       Date:  2016-10-18

8.  SkIndia Quiz 33: Solitary pigmented plaque containing a blue-gray papule.

Authors:  Cody J Connor; Brian L Swick
Journal:  Indian Dermatol Online J       Date:  2017 Jan-Feb

Review 9.  Current state of melanoma diagnosis and treatment.

Authors:  Lauren E Davis; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2019-08-01       Impact factor: 4.742

Review 10.  Conventional and Atypical Deep Penetrating Nevus, Deep Penetrating Nevus-like Melanoma, and Related Variants.

Authors:  Pavandeep Gill; Phyu P Aung
Journal:  Biology (Basel)       Date:  2022-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.